



Supplementary Figure 1: Histogram of *in vitro* nebulizer performances in terms of fine particle mass predicting the amount of tobramycin deposited in the lungs, extrathoracic dose predicting the amount of tobramycin and inhalable mass (fine particle mass + extrathoracic dose).

“Reprinted from *Journal of Cystic Fibrosis*, 10(2), Laurent Vecellio, Mohamed E. Abdelrahim, Jerome Montharu, Julien Galle, Patrice Diot, Jean-Christophe Dubus, Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin, 86-92, 2010, with permission from Elsevier.”